Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 53

Sort by

Sort Order Select

Journal Articles

Diagnosis, prognostic factors, and assessment of ALL in adults: 2024 ELN recommendations from a European expert panel

Nicola Gökbuget, Nicolas Boissel, Sabina Chiaretti, Hervé Dombret, Michael Doubek, Adele Fielding, Robin Foà, Sebastian Giebel, Dieter Hoelzer, Mathilde Hunault, David I. Marks, Giovanni Martinelli, Oliver Ottmann, Anita Rijneveld, Philippe Rousselot, Josep Ribera, Renato Bassan

Blood (2024) 143 (19): 1891–1902.

https://doi.org/10.1182/blood.2023020794

Published: 2024

Includes: Supplemental data

Journal Articles

Management of ALL in adults: 2024 ELN recommendations from a European expert panel

Blood (2024) 143 (19): 1903–1930.

https://doi.org/10.1182/blood.2023023568

Published: 2024

Includes: Supplemental data

Journal Articles

Sequential Chemotherapy and Blinatumomab to Improve Minimal Residual Disease in Adult Ph- B-Lineage Acute Lymphoblastic Leukemia. Final Results of the Phase II Gimema LAL2317 Trial

Blood (2023) 142 (Supplement 1): 826.

https://doi.org/10.1182/blood-2023-174973

Published: 2023

Journal Articles

LONG-TERM Results of the Frontline Dasatinib/Blinatumomabprotocol (D-ALBA, GIMEMA LAL2116) for Adult Ph+ Acutelymphoblastic Leukemia

Robin Foà, Renato Bassan, Loredana Elia, Alfonso Piciocchi, Stefano Soddu, Monica Messina, Felicetto Ferrara, Monia Lunghi, Antonino Mulè, Massimiliano Bonifacio, Nicola Fracchiolla, Prassede Salutari, Paola Fazi, Anna Guarini, Alessandro Rambaldi, Sabina Chiaretti

Blood (2023) 142 (Supplement 1): 4250.

https://doi.org/10.1182/blood-2023-187773

Published: 2023

Journal Articles

International, Prospective Study Comparing Nilotinib Versus Imatinib with Early Switch to Nilotinib to Obtain Sustained Treatment-Free Remission in Patients with Chronic Myeloid Leukemia (SUSTRENIM trial): Analysis of the Eligibility to Treatment Discontinuation

Blood (2023) 142 (Supplement 1): 3169.

https://doi.org/10.1182/blood-2023-182220

Published: 2023

Journal Articles

Selected Genomic Structural Variants Refine ELN-Based Prognostic Stratification of Patients with Acute Myeloid Leukemia and Normal Karyotype

Blood (2023) 142 (Supplement 1): 4317.

https://doi.org/10.1182/blood-2023-178599

Published: 2023

Journal Articles

Host immune system modulation in Ph + acute lymphoblastic leukemia patients treated with dasatinib and blinatumomab

Maria Cristina Puzzolo, Giulia Radice, Nadia Peragine, Maria Stefania de Propris, Paola Mariglia, Marco Vignetti, Antonella Vitale, Renato Bassan, Mario Annunziata, Gianluca Gaidano, Alessandro Rambaldi, Sabina Chiaretti, Anna Guarini, Robin Foà

Blood (2021) 138 (22): 2290–2293.

https://doi.org/10.1182/blood.2021011822

Published: 2021

Includes: Supplemental data

Journal Articles

Lenalidomide and Rituximab (ReRi) As Front-Line Chemo-Free Therapy for Elderly Frail Patients with Diffuse Large B-Cell Lymphoma. a Phase II Study of the Fondazione Italiana Linfomi (FIL)

Blood (2021) 138 (Supplement 1): 305.

https://doi.org/10.1182/blood-2021-148380

Published: 2021

Journal Articles

14q32 rearrangements deregulating BCL11B mark a distinct subgroup of T-lymphoid and myeloid immature acute leukemia

Blood (2021) 138 (9): 773–784.

https://doi.org/10.1182/blood.2020010510

Published: 2021

Includes: Supplemental data

Journal Articles

Lenalidomide and Rituximab (ReRi) As Front Line Chemo-Free Therapy of Elderly Frail Patients with Diffuse Large B-Cells Lymphoma. a Phase II Study of the Fondazione Italiana Linfomi (FIL)

Guido Gini, MD, Monica Tani, Alessandra Tucci, MD, Renato Bassan, MD, Filippo Ballerini, MD, Michela Sampaolo, Francesco Merli, MD, Francesca Re, Attilio Olivieri, Ombretta Annibali, Anna Marina Liberati, Carlo Visco, Annalisa Arcari, MD, Sergio Storti, MD, Alberto Fabbri, MD, Gerardo Musuraca, MD, Vittorio Ruggero Zilioli, MD, M. Christina Cox, MD PhD, Stefano Luminari, MD

Blood (2019) 134 (Supplement_1): 2880.

https://doi.org/10.1182/blood-2019-126568

Published: 2019

Journal Articles

Treatment of Adults with Minimal Residual Disease (MRD) Positive Acute Lymphoblastic Leukemia with Blinatumomab in a Real-World Setting: Results from the Neuf Study

Nicolas Boissel, MD PhD, Renato Bassan, MD, Josep-Maria Ribera, MD PhD, Sabina Chiaretti, MD PhD, Robin Foà, MD, Cristina Papayannidis, Naufil Alam, MSc, Alessandra Brescianini, PharmD, Isabella Pezzani, PharmD, Georg Kreuzbauer, MD, Alessandro Rambaldi, MD PhD

Blood (2019) 134 (Supplement_1): 2624.

https://doi.org/10.1182/blood-2019-122931

Published: 2019

Journal Articles

Treatment of Adults with Relapsed/Refractory Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia with Blinatumomab in a Real-World Setting: Results from the Neuf Study

Nicolas Boissel, MD PhD, Josep-Maria Ribera, MD PhD, Sabina Chiaretti, MD PhD, Alessandro Rambaldi, MD, Renato Bassan, MD, Cristina Papayannidis, Naufil Alam, MSc, Alessandra Brescianini, PharmD, Isabella Pezzani, PharmD, Georg Kreuzbauer, MD, Robin Foà, MD

Blood (2019) 134 (Supplement_1): 2627.

https://doi.org/10.1182/blood-2019-122917

Published: 2019

Journal Articles

Prognostic Impact of t(4;11)(q21;q23)/ KMT2A-AFF1 -Positivity in 926 BCR-ABL1 -Negative B-Lineage Acute Lymphoblastic Leukemia Patients Treated in Gimema Clinical Trials Since 1996

Alfonso Piciocchi, Monica Messina, Loredana Elia, Bs, Antonella Vitale, MD, Stefano Soddu, Anna Maria Testi, MD, Sabina Chiaretti, MD PhD, Marco Mancini, MD, Giorgina Specchia, MD, Antonio Spadano, MD, Mauro Krampera, Roberto Cairoli, MD, Francesco Di Raimondo, MD, Felicetto Ferrara, MD, Giuseppe Cimino, MD, Renato Bassan, MD, Paola Fazi, MD, Marco Vignetti, MD

Blood (2019) 134 (Supplement_1): 1469.

https://doi.org/10.1182/blood-2019-121977

Published: 2019

Journal Articles

Identification of a Chromatin-Splicing Mutational Signature to Define Secondary Acute Myeloid Leukemia: A Report from the Northern Italy Leukemia Group (NILG) Prospective Trial 02/06

Blood (2019) 134 (Supplement_1): 1443.

https://doi.org/10.1182/blood-2019-124497

Published: 2019

Journal Articles

Dasatinib-Blinatumomab Combination for the Front-Line Treatment of Adult Ph+ ALL Patients. Updated Results of the Gimema LAL2116 D-Alba Trial

Sabina Chiaretti, MD PhD, Renato Bassan, MD, Antonella Vitale, MD, Loredana Elia, Bs, Alfonso Piciocchi, Cristina Puzzolo, PhD, Martina Canichella, MD, Felicetto Ferrara, MD, Monia Lunghi, MD PhD, Francesco Fabbiano, MD, Massimiliano Bonifacio, MD, Nicola Fracchiolla, Prassede Salutari, MD, Alessandra Mancino, Bs, Marco Vignetti, MD, Anna Guarini, PhD, Alessandro Rambaldi, MD, Robin Foà, MD

Blood (2019) 134 (Supplement_1): 740.

https://doi.org/10.1182/blood-2019-128759

Published: 2019

Journal Articles

Clinical Impact of an Accurate Genetic Characterization of Older Acute Myeloid Leukemia Patients: A Report from the Northern Italy Leukemia Group (NILG) Randomized Trial 02/06

Blood (2018) 132 (Supplement 1): 434.

https://doi.org/10.1182/blood-2018-99-113869

Published: 2018

Journal Articles

Comparative Analysis between RQ-PCR, Digital-Droplet-PCR and Next-Generation-Sequencing (NGS) of Immunoglobulin/T-Cell Receptor Gene Rearrangements to Monitor Minimal Residual Disease in Adult Acute Lymphoblastic Leukemia Patients

Irene Della Starza, PhD, Lucia Anna De Novi, PhD, Alessandra Santoro, PhD, Salemi Domenico, PhD, Marzia Cavalli, PhD, Roberta Soscia, Francesca Paoloni, Lucia Menale, Valerio Apicella, Caterina Ilari, PhD, Antonella Vitale, Marco Vignetti, MD, Renato Bassan, MD, Sabina Chiaretti, MD PhD, Anna Guarini, PhD, Robin Foà, MD

Blood (2018) 132 (Supplement 1): 2828.

https://doi.org/10.1182/blood-2018-99-118219

Published: 2018

Journal Articles

Final Results of Northern Italy Leukemia Group (NILG) Trial 10/07 Combining Pediatric-Type Therapy with Minimal Residual Disease Study and Risk-Oriented Hematopoietic Cell Transplantation in Adult Acute Lymphoblastic Leukemia (ALL)

Blood (2016) 128 (22): 176.

https://doi.org/10.1182/blood.V128.22.176.176

Published: 2016

Journal Articles

The 'Next-in-Cml' Study: A Prospective Multicenter Study of Deep Sequencing of the BCR-ABL1 Kinase Domain in Philadelphia Chromosome-Positive Patients with Non-Optimal Responses to Tyrosine Kinase Inhibitor Therapy

Simona Soverini, Caterina De Benedittis, Stefania Stella, Anna Serra, Francesca Carnuccio, Santa Errichiello, PhD, Luana Bavaro, Fausto Castagnetti, MD, Alessandra Iurlo, MD, Nicola Orofino, MD, Federica Sorà, Simona Sica, Sara Galimberti, MD PhD, Claudia Baratè, Federica Mottadelli, Margherita Martelli, Elisabetta Novella, Eros Di Bona, MD, Giorgina Specchia, Francesco Albano, Elisabetta Abruzzese, MD, Fabio Ciceri, MD, Francesca Lunghi, MD, Carmen Fava, MD, Giovanna Rege Cambrin, MD, Luigia Luciano, Massimo Breccia, MD, Clementina Caracciolo, MD, Marco Santoro, Francesco Di Raimondo, MD, Gabriele Gugliotta, Cristina Papayannidis, MD PhD, Giovanni Cazzaniga, Manuela Mancini, Rosaria Sancetta, Renato Bassan, Caterina Musolino, MD, Giuseppina Spinosa, Silvana Franca Capalbo, Mario Annunziata, MD, Michele Cavo, MD, Gianantonio Rosti, Michele Baccarani, Paolo Vigneri, Giuseppe Saglio, MD, Fabrizio Pane, Giovanni Martinelli

Blood (2016) 128 (22): 3097.

https://doi.org/10.1182/blood.V128.22.3097.3097

Published: 2016

Journal Articles

Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome–positive ALL

Blood (2016) 128 (6): 774–782.

https://doi.org/10.1182/blood-2016-02-700153

Published: 2016

Includes: Supplemental data

NARROW

Diagnosis, prognostic factors, and assessment of ALL in adults: 2024 ELN recommendations from a European expert panel

Management of ALL in adults: 2024 ELN recommendations from a European expert panel

Sequential Chemotherapy and Blinatumomab to Improve Minimal Residual Disease in Adult Ph- B-Lineage Acute Lymphoblastic Leukemia. Final Results of the Phase II Gimema LAL2317 Trial

LONG-TERM Results of the Frontline Dasatinib/Blinatumomabprotocol (D-ALBA, GIMEMA LAL2116) for Adult Ph+ Acutelymphoblastic Leukemia

International, Prospective Study Comparing Nilotinib Versus Imatinib with Early Switch to Nilotinib to Obtain Sustained Treatment-Free Remission in Patients with Chronic Myeloid Leukemia (SUSTRENIM trial): Analysis of the Eligibility to Treatment Discontinuation

Selected Genomic Structural Variants Refine ELN-Based Prognostic Stratification of Patients with Acute Myeloid Leukemia and Normal Karyotype

Host immune system modulation in Ph + acute lymphoblastic leukemia patients treated with dasatinib and blinatumomab

Lenalidomide and Rituximab (ReRi) As Front-Line Chemo-Free Therapy for Elderly Frail Patients with Diffuse Large B-Cell Lymphoma. a Phase II Study of the Fondazione Italiana Linfomi (FIL)

14q32 rearrangements deregulating BCL11B mark a distinct subgroup of T-lymphoid and myeloid immature acute leukemia

Lenalidomide and Rituximab (ReRi) As Front Line Chemo-Free Therapy of Elderly Frail Patients with Diffuse Large B-Cells Lymphoma. a Phase II Study of the Fondazione Italiana Linfomi (FIL)

Treatment of Adults with Minimal Residual Disease (MRD) Positive Acute Lymphoblastic Leukemia with Blinatumomab in a Real-World Setting: Results from the Neuf Study

Treatment of Adults with Relapsed/Refractory Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia with Blinatumomab in a Real-World Setting: Results from the Neuf Study

Prognostic Impact of t(4;11)(q21;q23)/ KMT2A-AFF1 -Positivity in 926 BCR-ABL1 -Negative B-Lineage Acute Lymphoblastic Leukemia Patients Treated in Gimema Clinical Trials Since 1996

Identification of a Chromatin-Splicing Mutational Signature to Define Secondary Acute Myeloid Leukemia: A Report from the Northern Italy Leukemia Group (NILG) Prospective Trial 02/06

Dasatinib-Blinatumomab Combination for the Front-Line Treatment of Adult Ph+ ALL Patients. Updated Results of the Gimema LAL2116 D-Alba Trial

Clinical Impact of an Accurate Genetic Characterization of Older Acute Myeloid Leukemia Patients: A Report from the Northern Italy Leukemia Group (NILG) Randomized Trial 02/06

Comparative Analysis between RQ-PCR, Digital-Droplet-PCR and Next-Generation-Sequencing (NGS) of Immunoglobulin/T-Cell Receptor Gene Rearrangements to Monitor Minimal Residual Disease in Adult Acute Lymphoblastic Leukemia Patients

Final Results of Northern Italy Leukemia Group (NILG) Trial 10/07 Combining Pediatric-Type Therapy with Minimal Residual Disease Study and Risk-Oriented Hematopoietic Cell Transplantation in Adult Acute Lymphoblastic Leukemia (ALL)

The 'Next-in-Cml' Study: A Prospective Multicenter Study of Deep Sequencing of the BCR-ABL1 Kinase Domain in Philadelphia Chromosome-Positive Patients with Non-Optimal Responses to Tyrosine Kinase Inhibitor Therapy

Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome–positive ALL

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only